Last reviewed · How we verify
No IMiD treatment — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
No IMiD treatment (No IMiD treatment) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| No IMiD treatment TARGET | No IMiD treatment | Bristol-Myers Squibb | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- No IMiD treatment CI watch — RSS
- No IMiD treatment CI watch — Atom
- No IMiD treatment CI watch — JSON
- No IMiD treatment alone — RSS
Cite this brief
Drug Landscape (2026). No IMiD treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/no-imid-treatment. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab